ALZpath, Inc. has expanded its strategic agreement with Alamar Biosciences, Inc. (NASDAQ: ALMR), granting the precision proteomics company commercial rights to use ALZpath’s proprietary phosphorylated tau 217 antibody in blood-based diagnostic tests intended for clinical use. The July 23, 2026 agreement extends a collaboration that had previously focused on research-use-only assays and creates a route for Alamar, its customers and collaborators to develop in vitro diagnostic assays incorporating the antibody.
The announcement is strategically more important than a routine reagent supply extension. It moves Alamar closer to the regulated clinical diagnostics market while giving ALZpath another channel through which its pTau217 antibody could be incorporated into scalable laboratory platforms. However, neither company announced a named clinical test, regulatory submission, development timetable, exclusivity provision or financial terms, meaning the agreement creates commercial permission rather than an immediately marketable diagnostic product.
For Alamar Biosciences, the agreement connects its highly sensitive NULISA protein-detection technology with one of the most extensively studied blood biomarkers in Alzheimer’s disease. The central commercial question is now whether the companies can translate research performance into a reproducible, clinically validated and regulator-authorised assay that fits established laboratory workflows.
What does the expanded ALZpath and Alamar Biosciences agreement actually change?
ALZpath and Alamar Biosciences first entered into a strategic supply agreement in February 2024. That arrangement allowed Alamar to incorporate the ALZpath pTau217 antibody into its NULISAqpcr single-analyte assay and the multiplexed NULISAseq CNS Disease Panel 120, both positioned for research use rather than diagnostic procedures.
The expanded agreement broadens those rights into clinical diagnostics. According to ALZpath, Alamar and organisations using or collaborating with its platform can now develop in vitro diagnostic assays based on the antibody. That distinction matters because research-use-only products can support biomarker discovery, clinical trials and retrospective studies, but they cannot automatically be marketed as diagnostic tests for individual patient management.
The agreement therefore removes an intellectual property and commercial-access barrier, but it does not remove the scientific or regulatory barriers. Any future clinical assay will need a clearly defined intended use, analytical performance specifications, validated thresholds, appropriate reference standards, population-specific evidence and regulatory authorisation in each target jurisdiction.
The companies have not disclosed whether Alamar intends to develop a central laboratory test, a distributed in vitro diagnostic kit for the ARGO HT installed base, a partner-developed assay or several configurations. They have also not identified the patient population, such as cognitively impaired adults being evaluated by specialists, or whether the initial test would be positioned as a rule-out tool, a rule-in aid or part of a multistep diagnostic pathway.
These omissions are not necessarily weaknesses at this stage. They indicate that the collaboration is entering a development phase in which the final clinical product architecture remains to be determined.
Why is pTau217 becoming central to blood-based Alzheimer’s disease diagnostics?
Plasma pTau217 has attracted substantial clinical interest because elevated concentrations are strongly associated with Alzheimer’s disease pathology, particularly cerebral amyloid deposition. Blood testing could reduce dependence on more expensive or invasive procedures such as amyloid positron emission tomography imaging and cerebrospinal fluid collection, although test results still require interpretation alongside clinical findings and, in some cases, confirmatory evaluation.
A 2024 study published in JAMA Neurology evaluated the ALZpath pTau217 assay across 786 participants. The researchers reported area-under-the-curve values ranging from 0.92 to 0.96 for identifying elevated amyloid pathology and from 0.93 to 0.97 for tau pathology across the studied cohorts. A three-range interpretation model also reduced the proportion of participants requiring confirmatory testing by approximately 80% in that research setting.
Those findings provide a strong scientific foundation for the antibody, but they should not be interpreted as automatic validation of every assay that incorporates it. Diagnostic performance depends on the complete system, including antibody pairing, calibrators, detection chemistry, sample handling, instrument characteristics, algorithm design and the thresholds selected for the intended population.
The distinction is particularly important for Alamar because NULISA uses a different measurement platform from the system employed in the widely cited JAMA Neurology study. Alamar will need to demonstrate that any proposed clinical configuration preserves the required analytical sensitivity, specificity, precision and clinical classification performance on its own platform.
More recent research has reinforced pTau217’s ability to identify amyloid-positive individuals, while also illustrating the limitations of using the biomarker for every stage of Alzheimer’s disease. A 2026 study found that commercial pTau217 assays were highly useful for amyloid classification but became less precise when distinguishing the severity of tau accumulation among people who were already amyloid positive.
This means pTau217 may be especially valuable as an initial pathology-assessment tool, but it should not be treated as a complete substitute for disease staging, neurological evaluation or every form of confirmatory testing.
How could NULISA move from research assays into regulated clinical diagnostics?
Alamar’s NULISA platform is designed to measure very low concentrations of proteins in blood while supporting either targeted or multiplexed analysis. Its current neurology portfolio includes the NULISAqpcr brain-derived pTau217 assay, the research-use-only Alzheimer’s disease 5-plex assay and larger NULISAseq neurological panels.
The Alzheimer’s disease 5-plex assay simultaneously measures brain-derived pTau217, amyloid-beta 42, neurofilament light chain, glial fibrillary acidic protein and apolipoprotein E4 carrier status from one sample. This multiplexing capability could ultimately differentiate Alamar from companies developing single-analyte pTau217 tests, particularly if clinicians or laboratories prefer broader biological profiles covering amyloid-related pathology, neurodegeneration, inflammation and genetic risk.
The potential advantage is not simply the number of biomarkers. A clinically successful multiplex assay would need to demonstrate that combining the markers improves decision-making beyond a well-performing pTau217 test alone. Additional measurements can increase biological context, but they can also complicate validation, interpretation, quality control and reimbursement.
Alamar has separately expanded its research capabilities through the NULISAseq Neuro 220 Panel and an eMTBR-Tau assay intended to measure a blood marker associated with tau tangle burden. These additions suggest that the company is building a broader neurodegenerative disease platform rather than relying on one Alzheimer’s biomarker.
That strategy could support longitudinal research, patient stratification and therapeutic-development programmes. Clinical diagnostics, however, will require narrower claims supported by purpose-built evidence. A platform that can measure hundreds of proteins in research does not automatically need to expose clinicians to hundreds of results. The commercial product may instead need a tightly controlled panel whose outputs answer a specific clinical question.
The first practical challenge will be assay standardisation across instruments, laboratories, reagent lots and patient samples. Preanalytical variables such as collection tubes, processing delays, storage conditions, freeze-thaw cycles and kidney function can influence blood biomarker measurements. Clinical validation will therefore need to show that performance remains reliable outside specialised research cohorts.
What evidence supports the ALZpath antibody, and what must still be independently validated?
The ALZpath antibody has accumulated a meaningful body of published research and has become part of several commercial-development partnerships. In addition to Alamar Biosciences, ALZpath has announced agreements involving Roche, Beckman Coulter Diagnostics, Siemens Healthineers and Abbott, each targeting different high-throughput diagnostic platforms or laboratory settings.
This platform-agnostic licensing strategy positions ALZpath as an enabling biomarker company rather than a manufacturer dependent on one analyser. It could give the antibody access to a broad clinical laboratory footprint if multiple partners complete development and secure regulatory authorisations.
For Alamar, the presence of several established diagnostic companies in the same pTau217 ecosystem creates both validation and competitive pressure. Widespread partner interest supports the biological and commercial relevance of the target, but Alamar will need to show why a NULISA-based test offers a meaningful advantage in sensitivity, brain specificity, multiplexing, throughput, workflow or clinical interpretation.
The regulatory benchmark has also become clearer. In May 2025, the United States Food and Drug Administration cleared the Fujirebio Diagnostics Lumipulse G pTau217 and beta-amyloid 1-42 plasma ratio as an aid for detecting amyloid pathology in adults aged 55 years and older who exhibit signs and symptoms of cognitive decline. The agency specified that the test was not intended for general population screening or use as a stand-alone diagnostic.
The clearance was supported by a multicentre study involving 499 plasma samples. The United States Food and Drug Administration reported that 91.7% of participants with positive results had amyloid plaques confirmed by positron emission tomography or cerebrospinal fluid testing, while 97.3% of those with negative results had negative reference results. Fewer than 20% received an indeterminate result.
A future Alamar test would not necessarily need to copy that design, but it would face comparable expectations around reference standards, intended-use wording, false-positive and false-negative risk, indeterminate results and the role of confirmatory testing. The expanded ALZpath agreement should therefore be viewed as the beginning of a regulated development programme, not its conclusion.
How does the deal strengthen Alamar Biosciences’ commercial and investor narrative?
The clinical-diagnostics expansion arrives only months after Alamar Biosciences completed its April 2026 initial public offering. The company priced the offering at $17 per share and ultimately raised approximately $219.9 million in gross proceeds after the underwriters exercised their full option.
Alamar reported first-quarter 2026 revenue of $26 million, representing year-on-year growth of 99%. Consumables revenue increased by 178% to $14 million, while gross margin improved to 56%. The company nevertheless recorded a $12.3 million operating loss and a $21.3 million net loss, with the latter including an $8.6 million convertible-note remeasurement charge. Net proceeds from the initial public offering totalled approximately $197.8 million.
The growth in consumables is commercially relevant to the ALZpath agreement. Diagnostic assays used repeatedly across an installed instrument base could create a recurring revenue stream, potentially improving the economic value of every ARGO HT placement. However, regulated diagnostics also require investment in clinical studies, quality systems, manufacturing controls, regulatory functions and post-market support.
Alamar shares closed at approximately $25.88 on July 24, 2026. That was around 8.6% above the June 24 closing price of $23.83 and approximately 52% above the $17 initial public offering price. The shares were nearly unchanged over the five trading sessions from July 17 to July 24 and remained below their post-listing high of $29.43. Available market data placed the company’s market capitalisation at approximately $1.79 billion.
The shares increased from $25.24 on July 22 to approximately $25.89 on July 23, coinciding with the agreement announcement, although the movement cannot be attributed solely to the news. The broader market sentiment remains constructive, supported by strong revenue growth, the successful initial public offering and Alamar’s expanding neurology portfolio.
The valuation also raises the execution threshold. Investors are not valuing Alamar solely as an instrument supplier serving academic research. The share price appears to reflect expectations that its platform can expand across biopharmaceutical research, clinical development and eventually regulated diagnostics. The ALZpath agreement supports that narrative, but revenue from a future clinical assay is unlikely to be immediate.
What will determine whether the partnership produces a clinically adopted Alzheimer’s test?
The next meaningful milestone will be evidence that converts the commercial rights into a defined product-development programme. That could include disclosure of the intended clinical use, assay format, development partner, validation study, regulatory pathway or expected submission timeline.
Clinical adoption will depend on more than matching the accuracy reported in earlier research studies. Laboratories will assess instrument availability, sample throughput, calibration stability, quality-control procedures, training, turnaround time and cost. Clinicians will need clear interpretation rules, particularly for intermediate results and patients with comorbidities that could affect biomarker concentrations.
Payers and health systems will also examine whether the test reduces the need for positron emission tomography or lumbar puncture, accelerates appropriate specialist referral, improves therapy-selection workflows or lowers overall diagnostic expenditure. Analytical accuracy without evidence of clinical utility may be insufficient for broad coverage.
The agreement gives Alamar Biosciences a credible route into this market and extends ALZpath’s strategy of distributing its pTau217 antibody across multiple diagnostic platforms. Its significance lies in what it permits the companies to build, rather than in a finished test that clinicians can order immediately.
The commercial opportunity is substantial, but the decisive work remains ahead. Alamar must now show that NULISA’s research-level sensitivity can be converted into a standardised clinical assay with validated cutoffs, a defensible intended use and a practical place in the Alzheimer’s diagnostic pathway.
